Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci (Nasdaq: ABSI) announced participation in two investor conferences in New York. The company will host a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, and at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. Live and archived webcasts will be available on Absci’s investor relations website.
Absci (Nasdaq: ABSI) reported second quarter 2026 results and business updates, highlighted by positive interim Phase 1 data from the HEADLINE trial of ABS-201, an anti‑prolactin receptor antibody for pattern hair loss. Blinded interim data suggest a favorable safety profile and an estimated half‑life of at least 65 days, supporting a targeted dosing regimen of two or three injections over six months, pending further follow‑up.
The company completed a $100 million underwritten equity offering, including a $40 million strategic investment from Eli Lilly, yielding $93.6 million in net proceeds. Cash, cash equivalents, and marketable securities rose to $201.1 million at June 30, 2026, which Absci believes will fund operations into the second half of 2028. Q2 2026 revenue was $0.3 million versus $0.6 million a year earlier, with a net loss of $33.2 million compared to $30.6 million in Q2 2025, driven largely by higher R&D and SG&A expenses as internal programs, including ABS‑201, advance.
Absci (Nasdaq: ABSI) will report its second quarter 2026 business updates and financial and operating results after market close on Tuesday, August 11, 2026. Management will host a webcasted conference call at 4:30 p.m. Eastern Time, with live and replay access via the company’s investor relations website.
Absci (Nasdaq: ABSI) priced an underwritten public offering of 13,495,277 common shares at $7.41 per share, for expected gross proceeds of about $100 million.
According to Absci, funds will advance ABS-201 for androgenetic alopecia and endometriosis and support general corporate purposes, with closing expected June 25, 2026.
Absci (Nasdaq: ABSI) reported positive interim Phase 1 data from the HEADLINE trial of ABS-201, an investigational anti-PRLR antibody.
In 32 healthy volunteers across four single ascending dose cohorts (150–1800 mg IV), ABS-201 appeared well tolerated, with no serious adverse events and mostly mild TEAEs. Estimated half-life is at least 65 days, supporting potential dosing two or three times over six months. The multiple ascending dose phase in androgenetic alopecia participants has begun, with interim proof-of-concept data expected in 2H 2026 and full data in early 2027, and a Phase 2 endometriosis trial planned for later in 2026.
Absci (NASDAQ: ABSI) will participate in a Jones AI Day virtual panel on June 15, 2026, at 12:00 p.m. ET, alongside MindWalk (NASDAQ: HYFT) and a leading AI compute provider.
The discussion will cover AI, biological knowledge, and high-performance compute in drug discovery.
Absci (Nasdaq: ABSI) announced participation in two upcoming investor conferences in June 2026. Management will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with live and archived webcasts on its investor relations site.
Absci (Nasdaq: ABSI) reported Q1 2026 results and program updates. ABS-201 completed four SAD cohorts and is well tolerated; preliminary PK modeling supports a targeted dosing interval of two-to-three injections over six months. MAD dosing in AGA participants has begun. ABS-202 added to preclinical pipeline. Q2 2026 preliminary data and H2 2026 interim proof-of-concept expected. Financials: revenue $0.2M, R&D $19.3M, SG&A $9.1M, net loss $29.6M, cash and equivalents $125.7M; runway into H1 2028.
Absci (Nasdaq: ABSI) granted a non-statutory option for 276,200 shares to a newly hired non-executive employee on May 1, 2026 as an inducement under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The option carries an exercise price of $4.92 (closing price on the Grant Date), a 10-year term, and vests 25% after one year with the remaining 75% vesting in approximately equal monthly installments over the following 36 months, subject to continued service and plan terms.
Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Live audio and a replay will be available on the company investor relations website.